Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068718 · ClinicalTrials.gov registry record · Phase 1
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00068718 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 35 participants.
The verdict
NCT00068718, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic cell transplantation. White blood cells from donors may be able to kill cancer cells in patients with cancer that has come back (recurrent) after a donor hematopoietic cell transplant.
Interventions
- BIOLOGICAL Therapeutic Allogeneic Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2003-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068718
The ClinicalTrials.gov registry entry for NCT00068718 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Therapeutic Allogeneic Lymphocytes is the first listed.
NCT00068718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068718 about?
NCT00068718 is a clinical study titled "Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant". This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic cell transplantation. White blood cells from donors may be able to kill...
What is the current status of trial NCT00068718?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2003-05. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00068718?
The interventions under investigation include: Therapeutic Allogeneic Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00068718?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.